Short Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 47.9%

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 16,200 shares, a drop of 47.9% from the October 31st total of 31,100 shares. Based on an average trading volume of 1,620,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 2.0% of the shares of the stock are short sold.

Exicure Stock Performance

Shares of Exicure stock opened at $31.99 on Thursday. The stock has a 50 day moving average of $5.19 and a 200 day moving average of $2.23. The firm has a market capitalization of $69.42 million, a price-to-earnings ratio of -15.45 and a beta of 1.28. Exicure has a fifty-two week low of $1.44 and a fifty-two week high of $36.00.

Insider Activity

In related news, major shareholder Co. Ltd. Dgp acquired 237,223 shares of the stock in a transaction on Thursday, September 12th. The shares were bought at an average price of $3.00 per share, with a total value of $711,669.00. Following the completion of the purchase, the insider now owns 849,223 shares of the company’s stock, valued at approximately $2,547,669. This represents a 38.76 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.40% of the company’s stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.